Study summary

A one-time CRISPR gene-editing treatment resumed its phase 3 trial

Nex-z (MAGNITUDE) clinical hold lifted · Phase 3 (1,200 people) · FDA hold placed October 2025; lifted March 2026

What was tested

Nexiguran ziclumeran (nex-z), a single infusion that uses CRISPR to permanently switch off the TTR gene in the liver.

What they found

• The FDA paused the trials in October 2025 after a patient had severe liver injury and later died.
• The hold was lifted in March 2026 with closer liver monitoring and new exclusion criteria.

What it means

Could become a one-time treatment if efficacy and safety hold up.